Homocysteine lowering and cardiovascular events after acute myocardial infarction

New England Journal of Medicine

Volumn 354, Issue 15, 2006, Pages 1578-1588

  Bønaa, Kaare Harald ^a   Njølstad, Inger ^a   Ueland, Per Magne ^b   Schirmer, Henrik ^a   Tverdal, Aage ^c   Steigen, Terje ^d   Wang, Harald ^d   Nordrehaug, Jan Erik ^e   Arnesen, Egil ^a   Rasmussen, Knut ^d  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; SUDDEN DEATH; BLOOD; CEREBROVASCULAR ACCIDENT; DRUG COMBINATION; HEART INFARCTION; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; DEATH, SUDDEN, CARDIAC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; VITAMIN B 12; VITAMIN B 6;

EID: 33645796222     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa055227     Document Type: Article

References (41)

1. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
2. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
3. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
4. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
5. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
6. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.
7. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
8. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:6-13.
9. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998;97:437-43. [Erratum, Circulation 1999;99:983.]
10. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204-10.
11. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT. Low dietary folate intake is associated with an excess incidence of coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001;103:2674-80.
12. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
13. American Heart Association. Stroke deaths reduced by folic acid fortification: meeting report. March 5, 2004. (Accessed March 17, 2006, at http://www.americanheart.org/presenter.jhtml?identifier=3019554.)
14. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419. [Erratum, BMJ 2003;327:586.]
15. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
16. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke 2005;36:2404-9.
17. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
18. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81.
19. Windelberg A, Årseth O, Kvalheim G, Ueland PM. An automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. Clin Chem 2005;51:2103-9. [Erratum, Clin Chem 2006;52:342.]
20. O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol 1992;45:344-7.
21. Kelleher BP, Broin SD. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol 1991;44:592-5.
22. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol 1997;281:43-53.
23. Orlandini A, Diaz R, Wojdyla D, et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J 2006;27:527-33.
24. Baker F, Picton D, Blackwood S. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation 2002;106:Suppl II:II-2-II-741. abstract.
25. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.
26. Liem AH, van Boven AJ, Veeger NJ, et al. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 2004;93:175-9.
27. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
28. Lichtenstein AH, Russell RM. Essential nutrients: food or supplements? Where should the emphasis be? JAMA 2005;294:351-8.
29. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001;21:2072-9.
30. Vermeulen EG, Stehouwer CD, Valk J, et al. Effect of homocysteine- lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial. Eur J Clin Invest 2004;34:256-61.
31. Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC. Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. J Pharmacol Exp Ther 2002;303:158-62.
32. Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004;35:345-7.
33. Durga J, van Tits LJ, Schouten EG, Kok FJ, Verhoef P. Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial. Arch Intern Med 2005;165:1388-94.
34. Thambyrajah J, Landray MJ, Jones HJ, McGlynn FJ, Wheeler DC, Townend JN. A randomized double-blind placebo-controlled trial of the effect of homocysteinelowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol 2001;37:1858-63.
35. Doshi SN, Moat SJ, McDowell IF, Lewis MJ, Goodfellow J. Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? Atherosclerosis 2002;165:1-3.
36. Woodman RJ, Celermajer DE, Thompson PL, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. Clin Sci (Lond) 2004;106:353-8.
37. Dusitanond P, Eikelboom JW, Hankey GJ, et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke 2005;36:144-6.
38. Chia S, Wilson R, Ludlam CA, Webb DJ, Flapan AD, Newby DE. Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia: effects of vitamin supplementation. Clin Sci (Lond) 2005;108:65-72.
39. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004;62:S3-S12.
40. Driskell JA. Vitamin B-6 requirement of humans. Nutr Res 1994;14:293-324.
41. Matsubara K, Mori M, Akagi R, Kato N. Anti-angiogenic effect of pyridoxal 5′-phosphate, pyridoxal and pyridoxamine on embryoid bodies derived from mouse embryonic stem cells. Int J Mol Med 2004;14:819-23.